Sep 20 2022 Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder View
Aug 11 2022 Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results View
Aug 09 2022 Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder View
Aug 05 2022 Relmada Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022 View
Jul 21 2022 Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial View
Jun 07 2022 Relmada Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference View
Jun 02 2022 Relmada Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference View
May 25 2022 Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2022 Annual Meeting View
May 05 2022 Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results View
Apr 29 2022 Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology View
